Glenmark Pharmaceuticals settles patent litigation over anti-depressant drug

Published On 2015-12-21 04:15 GMT   |   Update On 2015-12-21 04:15 GMT
Advertisement
New Delhi: Glenmark Pharmaceuticals announced a patent litigation settlement with Forest Laboratories and Royalty Pharma Collection Trust over anti-depressant drug Savella.

The company and its US arm Glenmark Pharmaceuticals Inc have entered into a settlement agreement with Forest Laboratories LLC, Forest Laboratories Holdings Ltd and Royalty Pharma Collection Trust to settle the litigation.

Following the agreement, the outstanding patent litigation related to Glenmark's abbreviated new drug application (ANDA) for Milnacipran Hydrochloride 12.5 milligram, 25 mg, 50 mg, and 100 mg tablets, the generic version of Forest's Savella, will be dismissed.

"Under the terms of the settlement agreement, Glenmark will have the option to market and distribute its Milnacipran Hydrochloride tablets or an authorised generic version of Savella tablets," the company said in a BSE filing.

Other terms of the agreement are confidential, it added.

Citing IMS Health sales data for the 12-month period ending October 2015, Glenmark said Savella achieved annual sales of approximately USD 134.7 million.

Glenmark's current portfolio consists of 103 products authorised for distribution in the US marketplace and 63 ANDAs' pending approval with the USFDA, the company said.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News